Abstract
The preparation and biological evaluation of a novel series of dimeric camptothecin derivatives are described. All the new compounds showed a significant ability to inhibit human tumor cell growth with IC(50) values ranging from 0.03 to 12.2 μM. The interference with the activity of the nuclear enzymes topoisomerases has been demonstrated, highlighting the poison effect of one of the obtained byproducts toward topoisomerase I. A moderate antiangiogenic activity has been demonstrated for one of the obtained compounds. Moreover, the effects of four new compounds on caspases activity and ROS generation have been studied on transgenic mouse cell.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Camptothecin / analogs & derivatives
-
Camptothecin / chemical synthesis
-
Camptothecin / pharmacology
-
Caspases / drug effects
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
DNA Topoisomerases, Type I / drug effects*
-
Humans
-
Inhibitory Concentration 50
-
Mice
-
Reactive Oxygen Species
-
Structure-Activity Relationship
-
Topoisomerase I Inhibitors / chemical synthesis*
-
Topoisomerase I Inhibitors / chemistry
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Reactive Oxygen Species
-
Topoisomerase I Inhibitors
-
Caspases
-
DNA Topoisomerases, Type I
-
Camptothecin